The US Food and Drug Administration (FDA) has approved crizotinib for advanced-stage, ALK positive lung cancer as is also recommended by recent guidelines from professional organizations, including the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology, and National Comprehensive Cancer Network (NCCN). Here, ALK is linked to lung carcinoma.